- Previous Close
9.000 - Open
8.950 - Bid 8.010 x --
- Ask 8.940 x --
- Day's Range
8.940 - 8.950 - 52 Week Range
7.800 - 12.300 - Volume
2,500 - Avg. Volume
8,968 - Market Cap (intraday)
5.35B - Beta (5Y Monthly) -0.45
- PE Ratio (TTM)
-- - EPS (TTM)
-0.510 - Earnings Date --
- Forward Dividend & Yield 0.02 (0.22%)
- Ex-Dividend Date Jul 4, 2024
- 1y Target Est
13.96
Yunkang Group Limited operates as a medical operation service provider in the People's Republic of China. The company offers diagnostic testing services for medical institution alliances, including setting up or upgrading diagnostic centers, the establishment of standard operating procedures for diagnostic testing, diagnostic consultation and staff training, procurement of equipment, smart internet of things, and logistics assistance. It also provides diagnostic outsourcing services comprising pathology tests; infectious disease diagnostic tests, including hepatitis B virus, tuberculosis, human papilloma virus, EB virus, rabies virus, and nucleic acid tests for respiratory pathogens; genetic reproduction, and screening tests. In addition, the company offers routine diagnostic tests for chronic kidney, blood, autoimmune, endocrine metabolism, and other diseases. Further, it provides diagnostic testing services for financial institutions and insurance companies, including personalized diagnostic testing, medical report consultation, and hospital referral services; information technology, medical logistics, and medical equipment procurement; and healthcare technology development. The company provides its services through independent clinical laboratories and on-site diagnostic centers. Yunkang Group Limited was founded in 2008 and is headquartered in Guangzhou, the People's Republic of China.
www.yunkanghealth.com1,459
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: 2325.HK
View More
Performance Overview: 2325.HK
Trailing total returns as of 10/10/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 2325.HK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 2325.HK
View MoreValuation Measures
Market Cap
5.35B
Enterprise Value
5.11B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
6.15
Price/Book (mrq)
2.53
Enterprise Value/Revenue
5.83
Enterprise Value/EBITDA
189.17
Financial Highlights
Profitability and Income Statement
Profit Margin
-34.87%
Return on Assets (ttm)
-3.43%
Return on Equity (ttm)
-13.11%
Revenue (ttm)
794.58M
Net Income Avi to Common (ttm)
-277.1M
Diluted EPS (ttm)
-0.510
Balance Sheet and Cash Flow
Total Cash (mrq)
1.7B
Total Debt/Equity (mrq)
61.15%
Levered Free Cash Flow (ttm)
-58.96M
Research Analysis: 2325.HK
View MoreCompany Insights: 2325.HK
2325.HK does not have Company Insights